Itraconazole

1. Vulvovaginal candidosis, 2. Oropharyngeal candidosis, 3. g. tinea pedis, tinea cruris, tinea corporis, tinea manuum, 4. Pityriasis versicolor, 5. Onychomycosis caused by dermatophytes and/or yeasts, 6. The treatment of histoplasmosis, 7.

Itraconazole capsules is indicated in the following systematic fungal conditions when first-line systemic anti-fungal therapy is inappropriate or has proved ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

- Treatment of cryptococcosis (including cryptococcal meningitis): in immunocompromised patients with cryptococcosis and in all patients with cryptococcosis of the central nervous system. - Treatment of aspergillosis and candidosis.

- Maintenance therapy for penicilliosis and histoplasmosis only in AIDS patients. - Maintenance therapy of cryptococcal meningitis only in AIDS patients when standard therapy is considered inappropriate. Itraconazole capsules are also indicated for prophylaxis of fungal infections in immunocompromised patients with severe neutropenia when standard therapy is considered inappropriate.

MINT-ITRACONAZOLE (itraconazole) capsules are indicated for: • the treatment of the following systemic fungal infections in normal, predisposed or immunocompromised patients: 1. Invasive and non-invasive pulmonary aspergillosis. 2. Oral and/or esophageal candidiasis.

3. Chronic pulmonary histoplasmosis. 4. Cutaneous and lymphatic sporotrichosis. 5. Paracoccidioidomycosis. 6. (formerly chromomycosis) 7. Blastomycosis. The type of organism responsible for the infection should be isolated and identified and other relevant laboratory studies (wet mount, histopathology, serology) should be undertaken as appropriate to confirm diagnosis.

Therapy may be initiated prior to obtaining these results when clinically warranted; however, once these results become available, antifungal therapy should be adjusted accordingly. • the treatment of the following topical fungal infections in normal, predisposed or immunocompromised patients: 8.